Agilent Technologies Inc. has successfully completed its acquisition of clinical pathology company, Biocare Medical, from an investor group led by Excellere Partners and GHO Capital Partners LLP. Following the close of the transaction, Biocare is now part of Agilent’s Life Sciences and Diagnostics Markets Group.

Agilent continues to expect the acquisition to be accretive to the company’s top-line growth rate, margin profile and non-instrument revenue mix in the first year, and to become accretive to Agilent’s EPS approximately 12 months following close of the transaction. The expected impact on Agilent’s FY2026 financials will be provided as part of our third quarter earnings release. 

Visit Agilent for more information